Will Pandemics Become History? Cambridge’s AI-Designed Universal Vaccine Tested
A research team led by the University of Cambridge and its spin-out company DIOSynVax has developed a new ‘‘universal vaccine’’ technology that is poised to make a major impact in the medical world. Unlike traditional vaccines, this technology promises a fundamental solution to the problem of viruses constantly mutating to evade vaccines; it aims to provide broad protection against thousands of virus variants (such as coronaviruses or Ebola) with a single vaccine. The most remarkable aspect of the developed method is that, for the first time in medical history, a vaccine whose active ingredient (antigen) was designed entirely by computer simulations and artificial intelligence has been successfully tested on humans.
In the conducted Phase 1 clinical trial, the ‘‘pan-sarbecovirus’’ vaccine tested on 39 healthy volunteers was reported to be safe and showed no serious side effects. Analyzing all genetic sequence data obtained from global surveillance programs, the artificial intelligence designed a ‘‘super-antigen’’ that embodies the common features of the entire coronavirus family. The results demonstrated that the vaccine triggered immune responses to COVID-19 and SARS viruses, as well as bat viruses that could potentially spread from animals to humans and cause future pandemics. Furthermore, the vaccine was administered using a needle-free method with microfluidic jet technology, providing great convenience for those with a fear of needles.
The project’s scientific leader, Professor Jonathan Heeney, stated that with this technology, they have transformed vaccine development from a ‘‘reactive’’ structure that lags behind viruses into one that is ‘‘future-proof’’, likening the current vaccine systems’ constant attempts to catch mutations to ‘‘a dog chasing its own tail”. Professor Saul Faust from the University of Southampton, the study’s lead researcher, stated that if this new class of universal vaccines could be developed and clinically advanced before a pandemic begins, millions of lives could be saved, lockdowns could be avoided, and the economy could be protected. However, the true clinical success of this innovative vaccine, which has shown positive results in laboratory settings and with a limited number of volunteers, is not yet clear. Whether the vaccine will be effective in preventing global pandemics across a wider population with diverse age and genetic backgrounds remains a question mark. Therefore, whether the project, which is planned to begin Phase 2 clinical trials, will achieve its long-term goals is a matter of great interest in the medical world.